KG LEGAL \ INFO
BLOG

“For Research Use Only” Is Not a Legal Shieldgg

Publication date: November 16, 2026

Online sales of semaglutide and other active substances in Poland – regulatory exposure for sellers, marketplaces, advertisers and logistics operators

Vials of semaglutide and other peptides are sold online in Poland as “research chemicals” and delivered to parcel lockers without a prescription. The label is meant to keep the product outside pharmaceutical law. It does not: under EU and Polish law the classification of a product follows its presentation and its effect, not the seller’s disclaimer. For businesses, the practical question is therefore not whether this trade is legal, but who in the chain – seller, marketplace, advertiser, influencer, payment or logistics provider – carries the criminal, administrative and civil risk, and how quickly Polish enforcement tools are catching up.

More

The EU Pharma Package – the most far-reaching reform of EU pharmaceutical law in two decades

Publication date: November 12, 2026

After three years of negotiations, the reform of EU pharmaceutical legislation is one step away from completion. A new regulation and a new directive will replace the current Community code and the EMA Regulation, reshaping data and market protection periods, the rules for orphan medicines, the Bolar exemption and supply obligations. Originator and generic companies alike will need to revisit their strategies, and Poland faces a thorough overhaul of its Pharmaceutical Law.

More

Baskets of Equivalent Therapeutic Technologies – Rationalising Spending or Restricting Treatment Choice?

Publication date: October 05, 2026

Poland’s Ministry of Health wants to place medicines with different active substances in a single reimbursement limit group where they work in a similar way, and to reward hospitals for choosing the cheapest therapy available. The change is meant to bring prices down and free up funds for innovative treatment, but clinicians warn that cost equivalence is not the same as clinical equivalence. We examine how the proposed baskets of equivalent therapeutic technologies could affect physicians’ autonomy, patients’ rights and competition in the pharmaceutical market, and what safeguards the legislation should contain.
KG LEGAL KIELTYKA GLADKOWSKI supports international pharmaceutical, biotechnology and healthcare businesses operating in Poland. For legal assistance with pharmaceutical regulation, reimbursement and market access, contact our team at office@kg-legal.pl.

More

Artificial Intelligence in Healthcare: the Risks Behind the Promise

Publication date: November 04, 2026

Errors, bias, opacity, data security and the accountability gap – what patients, clinicians and regulators need to watch

Artificial intelligence is already reading scans, ranking medical literature, predicting kidney failure and managing hospital beds. Its potential to make medicine faster, more precise and more personalised seems almost limitless. Yet the same technology brings a distinct set of risks: algorithms that fail silently, tools used without adequate training, models that reproduce existing inequalities, decisions that no one can explain, patient data that is exposed or re-used, and a legal framework that still struggles to say who is responsible when something goes wrong. This article maps those risks and outlines what is needed to manage them.

More

Longevity Washing, AI and the Regulatory Fault Lines of the Longevity Industry: A European Perspective

Publication date: October 12, 2026

I. Introduction

The longevity economy is commonly estimated at several hundred billion dollars worldwide and continues to grow rapidly.[1] Venture capital flows into biotechnology companies that promise to slow, halt, or reverse aging. Clinics from Zurich to Seoul to Miami sell “longevity programmes.” Supplement brands attach the word “longevity” to products ranging from NAD precursors to collagen powders. And yet the word “longevity” does not exist as a legal category in European Union law. There is no definition, no register, no certification scheme, and no authority empowered to decide what may or may not describe itself as a longevity product, a longevity clinic, or a longevity company.

More

UP